vs
Side-by-side financial comparison of Amgen (AMGN) and ALTERITY THERAPEUTICS LTD (ATHE). Click either name above to swap in a different company.
Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. The company is ranked 18th on the list of largest biomedical companies by revenue. The name "AMGen" is a portmanteau of the company's original name, Applied Molecular Genetics.
Sarepta Therapeutics, Inc. is a medical research and drug development company with corporate offices and research facilities in Cambridge, Massachusetts, United States. Incorporated in 1980 as AntiVirals, shortly before going public the company changed its name from AntiVirals to AVI BioPharma soon with stock symbol AVII and in July 2012 changed name from AVI BioPharma to Sarepta Therapeutics and SRPT respectively. As of 2023, the company has four approved drugs.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $9.9B | — | ||
| Q3 25 | $9.6B | — | ||
| Q2 25 | $9.2B | — | ||
| Q1 25 | $8.1B | — | ||
| Q4 24 | $9.1B | — | ||
| Q3 24 | $8.5B | — | ||
| Q2 24 | $8.4B | — | ||
| Q1 24 | $7.4B | — |
| Q4 25 | $1.3B | — | ||
| Q3 25 | $3.2B | — | ||
| Q2 25 | $1.4B | — | ||
| Q1 25 | $1.7B | — | ||
| Q4 24 | $627.0M | — | ||
| Q3 24 | $2.8B | — | ||
| Q2 24 | $746.0M | — | ||
| Q1 24 | $-113.0M | — |
| Q4 25 | 69.8% | — | ||
| Q3 25 | 67.8% | — | ||
| Q2 25 | 67.2% | — | ||
| Q1 25 | 63.6% | — | ||
| Q4 24 | 65.7% | — | ||
| Q3 24 | 61.1% | — | ||
| Q2 24 | 61.4% | — | ||
| Q1 24 | 57.0% | — |
| Q4 25 | 27.6% | — | ||
| Q3 25 | 26.4% | — | ||
| Q2 25 | 28.9% | — | ||
| Q1 25 | 14.5% | — | ||
| Q4 24 | 25.4% | — | ||
| Q3 24 | 24.1% | — | ||
| Q2 24 | 22.8% | — | ||
| Q1 24 | 13.3% | — |
| Q4 25 | 13.5% | — | ||
| Q3 25 | 33.7% | — | ||
| Q2 25 | 15.6% | — | ||
| Q1 25 | 21.2% | — | ||
| Q4 24 | 6.9% | — | ||
| Q3 24 | 33.3% | — | ||
| Q2 24 | 8.9% | — | ||
| Q1 24 | -1.5% | — |
| Q4 25 | $2.45 | — | ||
| Q3 25 | $5.93 | — | ||
| Q2 25 | $2.65 | — | ||
| Q1 25 | $3.20 | — | ||
| Q4 24 | $1.17 | — | ||
| Q3 24 | $5.22 | — | ||
| Q2 24 | $1.38 | — | ||
| Q1 24 | $-0.21 | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
